The Affect Of Phosphatidylinositol 3-kinase Inhibitor LY294002 On Cell Proliferation And Chemotherapy In Mantle Cell Lymphoma

Objective: In the present study, we examined whether PI3 K inhibitor by LY294002 had effects on human mantle cell lymphoma and documented that LY294002 sensitized doxorubicin chemotherapy in human mantle cell lymphoma cell.So as to provides the experimental basis for improving clinical treatment effectiveness mantle cell lymphoma.Methods: Assessed proliferation of human mantle cell lymphoma and the IC50 of doxorubicin with MTT, on this basis,using flow cytometry to detect the change of cell cycle and apoptosis rate of Jeko-1 cell,testing the protein phosphorylation( Akt、RPS6K、4ebp1) of PI3 K signaling pathway with Western Blot.Results: 1.After processed by different concentration of LY294002 in different time, LY294002 inhibited the proliferation of Jeko-1 cells lines in a concentration-and time-dependent manner(P < 0.01).2.The cell cycle results showed that LY294002 blocked Jeko-1 cells in G1/G0 phase in a concentration-dependent manner(P<0.05). 3.LY294002 contributed to the apoptosis of Jeko-1 cells. 4.The results of Western Blott showed that LY294002 reduced the phosphorylation levels of PI3 K /Akt signaling pathway protein Akt,RPS6KA1,eIF4EBP1 lines in a concentration-and time-dependent manner(P<0.05). 5.LY294002 enhanced chemosensitivity of doxorubicin in Jeko-1 cells(P<0.05).Conclusion: In present study, we showed the evidence that that the PI3 K inhibitor LY294002 inhibit human mantle cell lymphoma proliferation and enhanced chemotherapy sensitivity of doxorubicin in human mantle cell lymphoma cells.The mechanism maybe by reducing the expression of p-Akt,p-RPS6KA1,p-eIF4EBP1 and induces the apoptosis of Jeko-1 cells ultimately.